InnovFin Infectious Diseases Finance Facility provides financial products ranging from standard debt to equity-type financing for amounts typically between EUR 7.5 million and EUR 75 million, to innovative players active in developing innovative vaccines, drugs, medical and diagnostic devices or novel research infrastructures for combatting infectious diseases.
InnovFin Advisory guides its clients on how to structure their R&I projects in order to improve their access to finance. The service helps them to capitalise on their strong points and adjust elements such as their business model, governance, funding sources and financing structure to improve their access to finance. In the long run, this increases their chances of being implemented.
Le volet Projets de démonstration liés à l’énergie d’InnovFin (« InnovFin Energy Demo Projects ») permet d’accorder des prêts, des garanties ou des financements de type apports de fonds propres, d’un montant compris entre 7,5 millions et 75 millions d’EUR, pour des projets inédits de démonstration à l’échelle commerciale portant sur la transformation du système énergétique.
InnovFin Science supports research and innovation (R&I) investments by research institutes, universities and research organisations (public or private), including the financing of buildings and other infrastructure directly related to R&I activity.
The EIB publishes a wide range of brochures aimed at both professionals and the general public. Information published in these documents and on the websites can be freely reproduced if the source is mentioned and information excerpts are not modified.